Improved Glycemic Control With Minimal Change in Medication Regimen Complexity in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic

The Annals of Pharmacotherapy
Candis M MorelloJan D Hirsch

Abstract

Gaining glycemic control in patients with type 2 diabetes (T2D) usually requires more complicated medication regimens. Increased medication regimen complexity (MRC) negatively impacts adherence and clinical outcomes. Compare MRC change in patients with uncontrolled T2D referred to a collaborative pharmacist-endocrinologist Diabetes Intense Medical Management (DIMM) clinic "tune up" model versus similar patients receiving usual primary care provider (PCP) care over 6 months. Retrospective, observational, comparative cohort study compared MRC of complex DIMM clinic patients to a similar group (adults with T2D, glycosylated hemoglobin [A1C] ≥8%), continuing to receive usual care from their PCPs. The MRC Index (MRCI) was used to quantify MRC. Both DIMM (n=99) and PCP (n=56) groups were similar, with high baseline mean MRC scores as measured by number of medications and MRCI (12.0 [SD=5.7] vs 13.7 [SD = 5.6], and 32.7 [SD=17.0] vs 38 [SD=16.5]), respectively. Mean MRC change over 6 months was not significantly different between groups, although mean A1C reduction was significantly greater in the DIMM versus PCP group (-2.4% [SD=2.1] vs -0.8% [SD=1.7], P<0.001, respectively). Outcomes represent the first report demonstrating how trea...Continue Reading

References

Nov 1, 1994·Journal of Clinical Epidemiology·M CharlsonJ Gold
Jul 22, 2004·The Annals of Pharmacotherapy·Johnson GeorgeKay Stewart
Dec 22, 2004·BMC Cancer·William H HallSrinivasan Vijayakumar
Feb 27, 2007·The Milbank Quarterly·Adam Oliver
Jan 22, 2009·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·M Odette Gore, Darren K McGuire
Jul 1, 2010·The New England Journal of Medicine·UNKNOWN ACCORD Study GroupLawrence J Fine
Jul 30, 2010·European Journal of Health Law·Colleen M Flood, Bryan Thomas
Apr 2, 2013·Clinical Therapeutics·Anne M LibbyJan D Hirsch
May 4, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Eric J IpDeempal C Bhatt
Sep 14, 2013·Journal of the American Pharmacists Association : JAPhA·Candis M MorelloKelly C Lee
Dec 20, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Izabela A Collier, David M Baker
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jan 4, 2017·The Annals of Pharmacotherapy·Alicia YehKajua B Lor
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Jan 26, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez

❮ Previous
Next ❯

Citations

Oct 17, 2019·Pharmacy : Journal of Pharmacy, Education and Practice·Linda AwdishuCandis M Morello

❮ Previous
Next ❯

Software Mentioned

MTM Spider Web
STATA
DIMM

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.